Introduction
============

Diabetes mellitus type 2 (T2DM) is known as one of the most common metabolic diseases. During the five years (from 2008 to 2012), the diabetes prevalence increased with a growth rate of 22.5% for the world and 23.4% for Iran[@R1]. The prevalence of diabetes in Iran is reported to be 9.9 to 13.6%[@R2],[@R3]. Obesity, dietary factors and inactive lifestyle are risk factors for T2DM[@R4],[@R5]. Also, genetic factors have a role in the occurrence and development of T2DM[@R6],[@R7].

The single nucleotide polymorphisms (SNPs) of the transcription factor 7-like 2 gene, on 10q25.3 locus, have showed strong association with T2DM risk in differentpopulations, however most loci have been reported to be associated with small effect sizes[@R8]. The single nucleotide polymorphisms within the TCF7L2 gene have the strongest effect on T2DM[@R9]. Also, this gene shows association with the risk of gestational diabetes and PTDM (Post transplantation diabetes mellitus)[@R10],[@R11]. Among the T2DM, the rs7903146(C/T) polymorphism of TCF7L2 gene have shown the most significant associations in nearly all populations and ethnics. However, the frequency of the rs7903146 risk allele is considerably less in Asian studies. Some studies reported no association with T2DM in some Asian ethnic populations[@R12],[@R13]

TCF7L2 as a transcription factor affects several intercellular functions. It acts as a member of the Wnt signaling pathway. With ligand banding of Wnt to it\'s receptor, the Wnt signaling pathway turns on. At the following, β-catenin interacts with BCL9 and translocate to the nucleus. The association of β-catenin with TCF7L2 in the nucleus result in the activation of some target genes such as proglucagon gene[@R14]. TCF7L2 represses the expression of proglucagon gene in endocrine cells[@R15],[@R16]. Recently, it was clear that disruption of the Wnt signaling pathway could lead to emerging T2DM. Wilfred et al show that the CT/TT genotypes of SNP rs7903146 are strongly associated with the risk of T2D in two independent cohorts. Their investigations on pancreatic islets cell of T2DM cases show the increase of TCF7L2 mRNA levels. Besides, the study of TCF7L2 expression in pancreatic islets of the T allele carriers show a considerable increase in mRNA production of TCF7L2, which is associated with abnormal insulin secretion and incretin efficacy[@R17].

Until now two incertins have been identified (GIP and GLP-1)[@R18]. GLP-1 is the central player in glucose homeostasis and insulin secretion. Thus, it is indicated that TCF7L2 genetic variants increase the risk of T2DM by altering GLP-1 levels[@R19] and affecting the beta cell proliferation and apoptosis level. The regulation of TCF7L2, the effects on the protein level and its outcomes are not perfectly understood. More investigations are needed to find out the molecular mechanism which an intronic region in TCF7L2 affects pancreatic islet function[@R20].

One of the genes affecting TCF7L2, which its association with T2DM has recently been found, is UBE2Z gene. This gene is located on 17q21.32 locus and includes 6 exons. It has been shown that UBE2Z has a high expression level in human tissues, especially in the pancreas. It has a major role in the ubiquitin system[@R21]. Ubiquitination is the process of binding ubiquitin protein to a cellular protein. Ubiquitin conjugating enzyme (E2) has a significant role in the ubiquitination process. Unfortunately not much information was detected about human UBE2Z[@R21]. However, the polymorphism rs46522 within the second intron of UBE2Z gene already was found to have an association with coronary heart disease and this association has been confirmed by subsequent studies[@R22]. Recently Johnson et al, by integrating the data from the TCF7L2 genoe-wide occupancy behavior study with cross referencing GWAS-derived statistics with specific data, and analyzing the result, revealed UBE2Z rs46522 as a novel type 2 diabetes locus[@R23]. To our knowledge no study has yet concerned the association of this SNP with T2DM in a case-control study. The aim of this study was to evaluate the association between the UBE2Z rs46522 and TCF7L2 rs7903146 variants with T2D in a khuzestanian population (south western Iran).

Materials and methods
=====================

Participants
------------

Total sample of this case -control study was 300 subjects randomly selected from the Khuzestan provinces situated in the south west of Iran and representative of Arab and non- Arab populations. The T2DM patients group were recognized based on ADA criteria (fasting plasma glucose ≥ 126 mg/dl and /or 2 h plasma glucose ≥ 200 mg/dl) and consist of 150 individuals (males/females:73/77). The control group too, consist of 150 individuals (males/females: 77/73) that were not recognized with T2DM according to clinical and laboratory examinations. For both case and control groups, personal data (age, gender, diabetes family history and the degree of obesity using the body mass index (BMI) and clinical data (fasting plasma glucose, triglyceride and total cholesterol) were analyzed. The rationale behind the minimum age selection was to ensure the absence of silent diabetics within the control group.

DNA genotyping
--------------

A 5 mL blood sample was collected in EDTA containing tubes and stored at -40°C for DNA extraction. Leukocyte genomic DNA was extracted from the blood specimen using salting- out method and was quantified by Nano Drop and agarose electrophoresis in order to being used in the polymerase chain reaction (PCR). Genotyping was done employing PCR-RFLP method. The TCF7L2 rs7903146 polymorphic site (C/T) was amplified by M-PCR (in Miss-match primer PCR; a Miss match base in the third position from 3′ end of forward primer in order to make restriction site for the restriction enzyme RsaI was used) using the primer pair 5′ - TTAGAGAGCTAAGCACTTTTTAGG TA - 3′( Miss-match forward primer) and 5′ - AGA GAT GAA ATG TAG CAG TGA AGT G - 3′ (reverse primer).

PCR was carried out by the use of a thermal cycler. TCF7L2 primers were designed based on previous study[@R24]. PCR cycling conditions included initial denaturation at 95°C for 4 minutes, 35 cycles of denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, extension at 72°C for 45 seconds, and final extension at 72°C for 5 minutes. PCR product (201-bp) was verified on 1.5% agarose gel using safe stain ([figure 1.A](#F1){ref-type="fig"}).
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The 201-bp product was digested with 0.8 µl of restriction enzyme RsaI for 4 hours at 37°C followed by 3% agarose gel electrophoresis gel. T-allele was not cleaved by RsaI and gave a 201-bp band, and C-allele was cleaved into two bonds 175-bp and 26-bp ([figure 1.B](#F1){ref-type="fig"}).

The rs46522 polymorphism (C/T) was amplified by the PCR method using the primer pair 5′-GCTCACCTCTCCGATTACAC-3′ (forward) and 5′-GGAAGGTTGGGAATAGGGC-3′ (reverse). The primers were designed employing Allel ID 6. Oligonucleotide primers were prepared from the Pishgam company for both PCRs. PCR conditions were as follows: initial denaturation at 95°C for 7 min, 35 cycles of denaturation at 95°C for 30 s, annealing at 57°C for 40s, extension at 72°C for 25s and final extension at 72°C for 10 min. PCR product (342-bp) was verified on 1.5% agarose gel ([figure 1.C](#F1){ref-type="fig"}). The PCR product was digested with 0.5 µl of Restriction enzyme BseGI (BtScI) at 55°C for 4 hours followed by 2.5 % agarose gel electrophoresis ([figure 1.D](#F1){ref-type="fig"}). The T-allele was not cleaved by BseGI and gave a 342-bp band and the T-allele was cleaved into two bonds 275- and 67-bp ([figure 1.D](#F1){ref-type="fig"}). Genotyping results were cofirmed by direct sequencing. Statistical analyses were performed bySPSS version 19.

Results
=======

Comparison between the control and T2DM patients shows no significant differences observed in distribution of number and sex (p\>0.05). But for age, significant differences between two groups were observed. Control subject were almost older than patients (56.75±7.37 vs. 52.46±7.37, P\<0.001). The result of comparison demographic and biochemical characteristics all subjects are shown in [Table 1](#T1){ref-type="table"}.

###### 

Clinical data of the study subjects

  ------------------------------------------------------------------
  Variable      Controls             Patients             P value
  ------------- -------------------- -------------------- ----------
  Sex,\         73/77(%48.7/%51.3)   77/73(%51.3/%48.7)   0.74
  male/female                                             

  Age, year     56.75 ± 7.37         52.46 ± 7.37         \< 0.001

  BMI, kg/m2    26.75 ± 4.25         28.92 ± 5.03         \< 0.001

  FBG, mg/dl    91.29 ± 6.38         172.2 ± 81.37        \< 0.001

  TC, mg/dl     184.31 ± 53.51       177.61 ± 48.48       \< 0.21

  TG, mg/dl     124.21 ± 58.42       145.02 ± 55.94       \< 0.001
  ------------------------------------------------------------------

The fasting blood glucose (FBG) and triglyceride (TG) were significantly higher in case group than the healthy individuals (P\<0.001). No significant difference was observed in total cholesterol (TC) between the two groups ([Table 1](#T1){ref-type="table"}).

For rs7903146, the T allele frequency of the cases and controls was 54.3 (%) and 58.0 (%) (P=0.37) respectively. The frequency of CC, CT and TT genotype were respectively 17.3%, 56.7% and 26.0% in patients and 8.7%, 66.7% and 24.7% in controls. The rs7903146 (C/T) polymorphism odds ratios for CC and TC genotypes were 1.9 (95% CI, 0.85 to 4.24; P=0.12) and 0.81 (95% CI, 0.47 to 1.38; P=0.43) compared with the TT genotype, respectively ([Table 2](#T2){ref-type="table"}).

###### 

Genotype analysis of patients and controls for rs7903146

  -------------------------------------------------------------------------
  Genotype/Allele   Patients\    Controls\    OR(95%CI)           P-value
                    N (%)        N (%)                            
  ----------------- ------------ ------------ ------------------- ---------
  CC                26 (17.3)    13 (8.7)     1.9 (0.85--4.24)    0.12

  CT                85 (56.7)    100 (66.7)   0.81 (0.47--1.38)   0.43

  TT                39 (26.0)    37 (24.7)    \-                  \-

  CC+CT             111 (74.0)   113(75.3)    1.09(0.76--1.55)    0.65

  TT+CT             124 (82.7)   137(91.3)    \-                  \-

  C                 137 (45.7)   126(42.0)    1.16(0.84--1.6)     0.37

  T                 163(54.3)    174(58.0)                        
  -------------------------------------------------------------------------

For rs46522, the T allele frequency of the cases and controls was 47.6 (%) and 41.6 (%) (P=0.14). The frequency of CC, CT and TT genotype were respectively 23.3%, 58.0% and 18.7% in patients and 30.7%, 55.3% and 14.0% in controls. The rs46522 (C/T) polymorphism odds ratios for TT and TC genotypes were 1.75 (95% CI, 0.86 to 3.59; P=0.13) and 1.38 (95% CI, 0.81 to 2.35; P=0.24) compared with the CC genotype, respectively ([Table 3](#T3){ref-type="table"}).

###### 

Genotype analysis of patients and controls for rs46522

  -------------------------------------------------------------------------
  Genotype/Allele   Patients\    Controls\    OR(95%CI)           P-value
                    N (%)        N (%)                            
  ----------------- ------------ ------------ ------------------- ---------
  CC                35 (23.3)    46 (30.7)    \-                  \-

  CT                87 (58.0)    83 (55.3)    1.38 (0.81--2.35)   0.24

  TT                27 (18.7)    21 (14.0)    1.75 (0.86--3.59)   0.13

  CC+CT             122 (51.5)   129 (55.4)   \-                  \-

  TT+CT             115 (48.5)   104(44.6)    1.17 (0.81--1.68)   0.4

  C                 157 (52.3)   175(58.3)    1.28 (.92--1.76)    0.14

  T                 143(47.6)    125(41.6)                        
  -------------------------------------------------------------------------

No significant difference in genotype frequencies was observed between T2DM patients and normoglycemic controls. Thus we found no association of rs46522 with T2DM and also our results on rs7903146 did not confirm the association of this widely replicated Variant of TCF7L2 gene with increased risk of T2DM in Khuzestan province.

Considering the genotypes frequency and statistical computations performed for gene pool of the entire population studied (300 n), not in study of rs46522 (with P-value of0.002) not in rs7903146 study (P\<0.001) The Hardy-Weinberg equilibrium (HWE) is not seen.

Discussion
==========

Diabetes mellitus is the eighth most frequent leading cause of death throughout the world and its prevalence is increasing worldwide. T2DM is the most frequent (90%) type of DM. Multiple genes and environmental factors affect the prevalence of T2DM[@R25]. The TCF7L2 locus has been shown to have a considerable effect on the pathogenesis of T2DM[@R22]. Among the 8 SNPs located within this gene, the most significant associations have been found between rs7903146 and T2DM risk in almost all groups, expect in some ethnic populations (such as some groups of Arabs)[@R12],[@R24]. Association between rs7903146 (C/T) and T2DM was already assessed in five studies in different states of Iran. In four of these studies (in Golestan, Ilam, Esfahan and Rafsanjan), the rs7903146 variant showed a positive significant association with T2DM. However, in another study (in Jahrom, Iran) this polymorphism showed lack of association with T2DM[@R24]--[@R29].

One of the genes affecting TCF7L2, whose association with T2DM has been recently found, is the UBE2Z gene. The product of this gene, UBE2Z enzyme has a major role in the ubiquitin system[@R21]. The polymorphism rs46522 within the second intron of this gene already was found to have an association with coronary heart disease and the association was confirmed by subsequent studies (22/a\>). Recently Johnson et al reported UBE2Z rs46522 as a novel T2DM locus[@R23]. We studied the association of rs46522 with T2DM for the first time in the Khuzestan province and in the world.

Our investigation shows no considerable difference in frequency of genotypes between control and cases groups. Thus we found no association of rs46522 with T2DM and also our results on rs7903146, did not confirm this variant\'s association with increased risk of T2DM in Khuzestan province population (including Arab and non-Arab), in contrast with previous reports in other states of Iran and many other part of the world. Differences in ethnic background in the world and within Iran, environmental effect, like life-style, and sample sizesof studies may explain these discrepancies. It is suggested to determine more precisely the effect sizes of both SNPs (rs46522 and rs7903146) in each major ethnic group in each area and with a larger sample size.

As mentioned in the study of Hardy Weinberg equilibrium, it was also revealed that in our study population for intended gene locus in this generation HWE is not seen. This result is expected, because for HWE there must be five conditions: 1) Large population size with random mating, 2) No mutation occurring, 3) No immigration,4) no natural selection, 5) No drift. Our studied population has a small size and there is almost high frequency of kinship marriage in Khuzestan province. Besides it is possible that the mutation, migration and natural selection also affected the population. As the current study is a statistical study and the gene locus studied showed no association with T2DM, it is not expected that increasing population size will lead to observing HWE in this case. Although increasing in population size in such studies may change the static analysis and the association results, still evolution forces (mutation, drift, immigration, natural selection and marriage) are active and effecting the gene pool and genotype frequencies.

As implicitly mentioned, a small sample size was one of the limitations of this study. F rom one side, the authorized time for this project was short, and on the other hand, we had some restrictions for selecting individuals. For instance, for more accurate results, the average age of normal individuals should have been more than the average age of patients. The individuals must have been native of Khuzestan prvince, based on project definition. The individuals number of both sexes (male and female) should have been almost equal. The normal individuals must have no family history of T2DM and the age of patients must have not been under 30 years old. So the existence of these restrictions made us unable to accumulate more samples within the time frame defined for the project.
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